--- type: "firecrawl-provider" description: "California's prescription drug cost transparency reports (CTRx, SB 17) from the Department of Health Care Access and Information (HCAI), published on the CalHHS Open Data Portal. Manufacturers report wholesale acquisition cost (WAC, list price) increases of more than 16% over three years for drugs costing over $40 per course of therapy, with the increase, the new WAC, patent expiry, sales, their stated reasons and any acquisition, plus a five-year WAC history per report; and new drugs introduced at a WAC above the Medicare Part D specialty-drug threshold, with launch WAC, marketing and pricing plan, estimated patients and FDA breakthrough and priority review flags. The current year's monthly update and annual files back to 2019, searchable by drug, NDC, manufacturer and date, with derived increase percentages including the statute's three-year measure. CC BY; every result carries HCAI's attribution." use_when: "California's prescription drug cost transparency reports (CTRx, SB 17) from the Department of Health Care Access and Information (HCAI), published on the CalHHS Open Data Portal. Manufacturers report wholesale acquisition cost (WAC, list price) increases of more than 16% over three years for drugs costing over $40 per course of therapy, with the increase, the new WAC, patent expiry, sales, their stated reasons and any acquisition, plus a five-year WAC history per report; and new drugs introduced at a WAC above the Medicare Part D specialty-drug threshold, with launch WAC, marketing and pricing plan, estimated patients and FDA breakthrough and priority review flags. The current year's monthly update and annual files back to 2019, searchable by drug, NDC, manufacturer and date, with derived increase percentages including the statute's three-year measure. CC BY; every result carries HCAI's attribution.\n\nCalifornia's prescription drug cost transparency reports (CTRx, SB 17) from the Department of Health Care Access and Information (HCAI), published on the CalHHS Open Data Portal. Manufacturers report wholesale acquisition cost (WAC, list price) increases of more than 16% over three years for drugs costing over $40 per course of therapy, with the increase, the new WAC, patent expiry, sales, their stated reasons and any acquisition, plus a five-year WAC history per report; and new drugs introduced at a WAC above the Medicare Part D specialty-drug threshold, with launch WAC, marketing and pricing plan, estimated patients and FDA breakthrough and priority review flags. The current year's monthly update and annual files back to 2019, searchable by drug, NDC, manufacturer and date, with derived increase percentages including the statute's three-year measure. CC BY; every result carries HCAI's attribution." categories: "Life sciences" capabilities: 2 credits_per_call: 5 --- # California HCAI prescription drug price reports (WAC increases and new drugs) on Firecrawl Alexandria California's prescription drug cost transparency reports (CTRx, SB 17) from the Department of Health Care Access and Information (HCAI), published on the CalHHS Open Data Portal. Manufacturers report wholesale acquisition cost (WAC, list price) increases of more than 16% over three years for drugs costing over $40 per course of therapy, with the increase, the new WAC, patent expiry, sales, their stated reasons and any acquisition, plus a five-year WAC history per report; and new drugs introduced at a WAC above the Medicare Part D specialty-drug threshold, with launch WAC, marketing and pricing plan, estimated patients and FDA breakthrough and priority review flags. The current year's monthly update and annual files back to 2019, searchable by drug, NDC, manufacturer and date, with derived increase percentages including the statute's three-year measure. CC BY; every result carries HCAI's attribution. - Categories: Life sciences - Category index: [Life sciences category](https://firecrawl.dev/alexandria/agents/categories/life-sciences) - Provider key: `data-chhs-ca-gov` - Access: Firecrawl credits - Cost: 5 credits per call ## More - [Human guide](https://firecrawl.dev/app/alexandria/data-chhs-ca-gov) - [OpenAPI spec](https://firecrawl.dev/alexandria/agents/providers/data-chhs-ca-gov/openapi.json) ## Capabilities - [Search](https://firecrawl.dev/alexandria/agents/providers/data-chhs-ca-gov/wac-increases/search): Manufacturer-reported wholesale acquisition cost (WAC) increases for prescription drugs, from California HCAI's CTRx reports: per NDC, the WAC effective date, increase amount and WAC after it, the derived WAC before, percent increase and the statute's three-year percent increase, patent expiry, drug source type, sales, the manufacturer's stated cost increase factors and changes or improvements, acquisition details, and the five-year WAC history behind each report. Filter by drug, manufacturer, NDC, effective date, minimum percent increase and Brand or Generic; one year's file per call (the current year to date by default, annual files back to 2019). No match is an empty result. - [Launch search](https://firecrawl.dev/alexandria/agents/providers/data-chhs-ca-gov/drug-launches/launch_search): New prescription drugs introduced to market at a WAC above the Medicare Part D specialty-drug threshold, as manufacturers reported them to California HCAI (CTRx): per NDC, the introduction date, WAC at introduction, the manufacturer's marketing and pricing plan, estimated number of patients, FDA breakthrough therapy and priority review flags, and acquisition details. Filter by drug, manufacturer, NDC, introduction date, minimum WAC, Brand or Generic and the two FDA flags; one year's file per call (the current year to date by default, annual files back to 2019). No match is an empty result. ## 1. Choose this provider when California's prescription drug cost transparency reports (CTRx, SB 17) from the Department of Health Care Access and Information (HCAI), published on the CalHHS Open Data Portal. Manufacturers report wholesale acquisition cost (WAC, list price) increases of more than 16% over three years for drugs costing over $40 per course of therapy, with the increase, the new WAC, patent expiry, sales, their stated reasons and any acquisition, plus a five-year WAC history per report; and new drugs introduced at a WAC above the Medicare Part D specialty-drug threshold, with launch WAC, marketing and pricing plan, estimated patients and FDA breakthrough and priority review flags. The current year's monthly update and annual files back to 2019, searchable by drug, NDC, manufacturer and date, with derived increase percentages including the statute's three-year measure. CC BY; every result carries HCAI's attribution. California's prescription drug cost transparency reports (CTRx, SB 17) from the Department of Health Care Access and Information (HCAI), published on the CalHHS Open Data Portal. Manufacturers report wholesale acquisition cost (WAC, list price) increases of more than 16% over three years for drugs costing over $40 per course of therapy, with the increase, the new WAC, patent expiry, sales, their stated reasons and any acquisition, plus a five-year WAC history per report; and new drugs introduced at a WAC above the Medicare Part D specialty-drug threshold, with launch WAC, marketing and pricing plan, estimated patients and FDA breakthrough and priority review flags. The current year's monthly update and annual files back to 2019, searchable by drug, NDC, manufacturer and date, with derived increase percentages including the statute's three-year measure. CC BY; every result carries HCAI's attribution. ## 2. Minimal request Call `POST https://api.firecrawl.dev/v2/scrape` with `{ alexandria: { provider, capability, options } }`. For a batch, send `{ alexandria: [...] }` with up to 10 calls. ```json { "provider": "data-chhs-ca-gov", "capability": "wac-increases/search", "options": { "limit": 10, "min_increase_percent": 16, "sort": "increase_percent_desc" } } ``` ## 3. Add provider options Use only the options needed for the task: - `drug` (string): Drug product description to match, case-insensitively anywhere in it: a brand (`skyrizi`, `Fyarro`), an ingredient as the manufacturer wrote it, a strength or a package form. Example: `` - `drug_category` (string): Brand or Generic, as the manufacturer classified the drug. Only the current year's monthly file reports it; with an annual year this is invalid_input. Example: `Brand` - `effective_from` (string): Only increases whose WAC effective date is on or after this date (YYYY-MM-DD). Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `effective_to` (string): Only increases whose WAC effective date is on or before this date (YYYY-MM-DD). Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `include_history` (boolean): Read the year's five-year WAC history file and attach each report's WAC changes (`history`) and the derived `three_year_increase_percent`. Defaults to true when `drug` or `ndc` is given, false otherwise. Example: `false` - `limit` (number): Reports per page. Example: `25` - `manufacturer` (string): Manufacturer name to match, case-insensitively anywhere in it: `AbbVie`, `pfizer`, `Teva`. Example: `` - `min_increase_percent` (number): Only increases of at least this percent over the WAC just before them (`increase_percent`, derived). The statute measures against the WAC three years earlier instead (`three_year_increase_percent`). Example: `10` - `ndc` (string): An NDC-11 as 11 digits (`80803015350`) or hyphenated 5-4-2 (`80803-0153-50`), a hyphenated 10-digit NDC (`0074-2100-01`, 4-4-2, 5-3-2 or 5-4-1, padded to 5-4-2), or an NDC-9 product code (`80803-0153`, `808030153`) matching all its packages. A bare 10-digit NDC is ambiguous and rejected. Example: `80803015350` - `offset` (number): Reports to skip; pass `next_offset` from the previous page. Example: `0` - `sort` (string): Order of results: latest WAC effective date first (default), or largest `increase_percent` first. Example: `effective_date_desc` - `year` (number): Calendar year of the report file to read: the current year reads HCAI's monthly update (the year to date), earlier years their Q1-Q4 annual file. Defaults to the latest year published. A year without a file is invalid_input listing the years available. HCAI's 2020 annual WAC increase file is published with its rows out of line with its header (no row's prices match its own five-year history), so 2020 is not served and is invalid_input like a year without a file. Example: `2019` ## 4. Request through your preferred interface ### JavaScript ```javascript const result = await firecrawl.scrape({ alexandria: { provider: "data-chhs-ca-gov", capability: "wac-increases/search", options: { limit: 10, min_increase_percent: 16, sort: "increase_percent_desc", }, }, }); ``` ### Python ```python result = firecrawl.scrape_alexandria({ "provider": "data-chhs-ca-gov", "capability": "wac-increases/search", "options": { "limit": 10, "min_increase_percent": 16, "sort": "increase_percent_desc" } }) ``` ### cURL ```sh curl https://api.firecrawl.dev/v2/scrape \ -H "Authorization: Bearer $FIRECRAWL_API_KEY" \ -H "Content-Type: application/json" \ -d '{ "alexandria": { "provider": "data-chhs-ca-gov", "capability": "wac-increases/search", "options": { "limit": 10, "min_increase_percent": 16, "sort": "increase_percent_desc" } } }' ``` ### CLI ```sh firecrawl scrape 'data-chhs-ca-gov/wac-increases/search' \ --options '{"limit":10,"min_increase_percent":16,"sort":"increase_percent_desc"}' ``` ### MCP Call the FCX MCP retrieve tool with this object: ```json { "provider": "data-chhs-ca-gov", "capability": "wac-increases/search", "options": { "limit": 10, "min_increase_percent": 16, "sort": "increase_percent_desc" } } ``` Ask for only the returned fields needed by the task. ## 5. Full request shape ```json { "provider": "data-chhs-ca-gov", "capability": "wac-increases/search", "options": { "limit": 10, "min_increase_percent": 16, "sort": "increase_percent_desc" } } ``` ## 6. Response data The response includes `success`, `provider`, `capability`, `creditsCost` and `data`. This example shows the provider payload in `data`: ```json { "file_name": "wac-increase-data-jan-sept-2026.csv", "file_url": "https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-sept-2026.csv", "history_file_url": null, "license": { "attribution": "Source: California Department of Health Care Access and Information (HCAI), Cost Transparency Report on prescription drugs (CTRx), Prescription Drug Wholesale Acquisition Cost (WAC) Increases, published on the California Open Data Portal under CC BY.", "name": "Creative Commons Attribution (CC BY)", "url": "https://data.ca.gov/dataset/prescription-drug-wholesale-acquisition-cost-wac-increases" }, "next_offset": 10, "results": [ { "acquisition": { "acquired_from": "Pierre Fabre Pharmaceuticals Inc.", "date": "2026-02-27", "price": 14000000, "price_comment": null, "price_nonpublic": false, "wac_at_acquisition": 625.38, "wac_at_introduction": 375, "wac_year_prior_to_acquisition": 625.38, "year_introduced": 2014 }, "change_improvement_description": "No change or improvement.", "change_improvement_nonpublic": false, "cost_increase_factors": null, "cost_increase_factors_nonpublic": true, "date_reported": "2026-07-30", "drug_category": "Brand", "drug_product_description": "Hemangeol (propranolol hydrochloride) Oral Solution, 4.28 mg/ mL, 120 mL bottle", "drug_source_type": "Single Source Drug", "general_comments": null, "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 699.51, "manufacturer": "Eton Pharmaceuticals, Inc.", "manufacturer_id": "Rx0000270", "ndc": "71863013212", "ndc_5_4_2": "71863-0132-12", "patent_expiration_date": "2028-10-16", "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 5000, "wac_before_increase": 625.38, "wac_effective_date": "2026-05-11", "wac_increase_amount": 4374.62 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-02-13", "drug_category": "Generic", "drug_product_description": "TRIHEXYPHENIDYL HYDROCHLORIDE 0.4mg/mL Oral Solution, 473mL Bottle [Qty: 1]", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": null, "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 480, "manufacturer": "Pharmaceutical Associates, Inc", "manufacturer_id": "Rx0000135", "ndc": "00121065816", "ndc_5_4_2": "00121-0658-16", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 247.37, "wac_before_increase": 42.65, "wac_effective_date": "2026-02-02", "wac_increase_amount": 204.72 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Brand", "drug_product_description": "Hydromorphone Hydrochloride 2 mg/ml per Single-Dose vial 10", "drug_source_type": "Innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377.01, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409336510", "ndc_5_4_2": "00409-3365-10", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 202.06, "wac_before_increase": 42.36, "wac_effective_date": "2026-01-01", "wac_increase_amount": 159.7 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Butorphanol Tartrate 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial 10", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409162602", "ndc_5_4_2": "00409-1626-02", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 931.77, "wac_before_increase": 195.34, "wac_effective_date": "2026-01-01", "wac_increase_amount": 736.43 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Brand", "drug_product_description": "Demerol™ 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial 1", "drug_source_type": "Innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409118130", "ndc_5_4_2": "00409-1181-30", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 655.45, "wac_before_increase": 137.41, "wac_effective_date": "2026-01-01", "wac_increase_amount": 518.04 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Dextran 500 mL (10% LMD in 0.9% Sodium Chloride) Flexible Container 12", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409741903", "ndc_5_4_2": "00409-7419-03", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 3972.41, "wac_before_increase": 832.79, "wac_effective_date": "2026-01-01", "wac_increase_amount": 3139.62 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Dextran 500 mL (10% LMD in 5% Dextrose) Flexible Container 12", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409741803", "ndc_5_4_2": "00409-7418-03", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 3809.94, "wac_before_increase": 798.73, "wac_effective_date": "2026-01-01", "wac_increase_amount": 3011.21 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Hydromorphone Hydrochloride 10 mg/mL (10 mg/mL) Single Dose Glass Fliptop Vial 10", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409263401", "ndc_5_4_2": "00409-2634-01", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 780.56, "wac_before_increase": 163.64, "wac_effective_date": "2026-01-01", "wac_increase_amount": 616.92 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Verapamil Hydrochloride 2.5 mg/mL (5 mg/2 mL) Glass Ampul 5", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409401101", "ndc_5_4_2": "00409-4011-01", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 436.5, "wac_before_increase": 91.51, "wac_effective_date": "2026-01-01", "wac_increase_amount": 344.99 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Brand", "drug_product_description": "Hydromorphone Hydrochloride 4 mg/mL (4 mg/1 mL) Carpuject™ Luer Lock Glass Syringe (no needle) 10", "drug_source_type": "Innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 376.95, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409130431", "ndc_5_4_2": "00409-1304-31", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 150, "wac_before_increase": 31.45, "wac_effective_date": "2026-01-01", "wac_increase_amount": 118.55 } ], "source_updated_at": "2026-10-05", "source_url": "https://data.chhs.ca.gov/dataset/prescription-drug-wholesale-acquisition-cost-wac-increases", "total_count": 100, "year": 2026 } ``` ## API reference-derived contract The following capability contract is generated from the same normalized Alexandria API reference exposed in the API spec. ### Search - Capability: `wac-increases/search` - Description: Manufacturer-reported wholesale acquisition cost (WAC) increases for prescription drugs, from California HCAI's CTRx reports: per NDC, the WAC effective date, increase amount and WAC after it, the derived WAC before, percent increase and the statute's three-year percent increase, patent expiry, drug source type, sales, the manufacturer's stated cost increase factors and changes or improvements, acquisition details, and the five-year WAC history behind each report. Filter by drug, manufacturer, NDC, effective date, minimum percent increase and Brand or Generic; one year's file per call (the current year to date by default, annual files back to 2019). No match is an empty result. - Instructions: Pick it for list price (WAC) increases manufacturers reported to California and the reasons they gave: "which drugs rose more than 16% this year", "how much did AbbVie raise Skyrizi's WAC and how has it moved over five years", "what did the manufacturer say drove this increase". It covers only reported increases (those over California's threshold, and some below it), not a full WAC price list; a drug without a report has no row. For launch prices of new drugs use drug-launches/launch_search. For Medicare Part B payment limits use cms-gov asp-pricing/payment_limits; for what pharmacies pay (NADAC) use data-medicaid-gov prices/search. - Cost: 5 credits per call - Capability file: [Search](https://firecrawl.dev/alexandria/agents/providers/data-chhs-ca-gov/wac-increases/search) Accepted options: - `drug` (string): Drug product description to match, case-insensitively anywhere in it: a brand (`skyrizi`, `Fyarro`), an ingredient as the manufacturer wrote it, a strength or a package form. Example: `` - `drug_category` (string): Brand or Generic, as the manufacturer classified the drug. Only the current year's monthly file reports it; with an annual year this is invalid_input. Example: `Brand` - `effective_from` (string): Only increases whose WAC effective date is on or after this date (YYYY-MM-DD). Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `effective_to` (string): Only increases whose WAC effective date is on or before this date (YYYY-MM-DD). Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `include_history` (boolean): Read the year's five-year WAC history file and attach each report's WAC changes (`history`) and the derived `three_year_increase_percent`. Defaults to true when `drug` or `ndc` is given, false otherwise. Example: `false` - `limit` (number): Reports per page. Example: `25` - `manufacturer` (string): Manufacturer name to match, case-insensitively anywhere in it: `AbbVie`, `pfizer`, `Teva`. Example: `` - `min_increase_percent` (number): Only increases of at least this percent over the WAC just before them (`increase_percent`, derived). The statute measures against the WAC three years earlier instead (`three_year_increase_percent`). Example: `10` - `ndc` (string): An NDC-11 as 11 digits (`80803015350`) or hyphenated 5-4-2 (`80803-0153-50`), a hyphenated 10-digit NDC (`0074-2100-01`, 4-4-2, 5-3-2 or 5-4-1, padded to 5-4-2), or an NDC-9 product code (`80803-0153`, `808030153`) matching all its packages. A bare 10-digit NDC is ambiguous and rejected. Example: `80803015350` - `offset` (number): Reports to skip; pass `next_offset` from the previous page. Example: `0` - `sort` (string): Order of results: latest WAC effective date first (default), or largest `increase_percent` first. Example: `effective_date_desc` - `year` (number): Calendar year of the report file to read: the current year reads HCAI's monthly update (the year to date), earlier years their Q1-Q4 annual file. Defaults to the latest year published. A year without a file is invalid_input listing the years available. HCAI's 2020 annual WAC increase file is published with its rows out of line with its header (no row's prices match its own five-year history), so 2020 is not served and is invalid_input like a year without a file. Example: `2019` Response schema example: ```json { "file_name": "wac-increase-data-jan-sept-2026.csv", "file_url": "https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/dda8a083-bc81-4f6d-b02f-935a2df70328/download/wac-increase-data-jan-sept-2026.csv", "history_file_url": null, "license": { "attribution": "Source: California Department of Health Care Access and Information (HCAI), Cost Transparency Report on prescription drugs (CTRx), Prescription Drug Wholesale Acquisition Cost (WAC) Increases, published on the California Open Data Portal under CC BY.", "name": "Creative Commons Attribution (CC BY)", "url": "https://data.ca.gov/dataset/prescription-drug-wholesale-acquisition-cost-wac-increases" }, "next_offset": 10, "results": [ { "acquisition": { "acquired_from": "Pierre Fabre Pharmaceuticals Inc.", "date": "2026-02-27", "price": 14000000, "price_comment": null, "price_nonpublic": false, "wac_at_acquisition": 625.38, "wac_at_introduction": 375, "wac_year_prior_to_acquisition": 625.38, "year_introduced": 2014 }, "change_improvement_description": "No change or improvement.", "change_improvement_nonpublic": false, "cost_increase_factors": null, "cost_increase_factors_nonpublic": true, "date_reported": "2026-07-30", "drug_category": "Brand", "drug_product_description": "Hemangeol (propranolol hydrochloride) Oral Solution, 4.28 mg/ mL, 120 mL bottle", "drug_source_type": "Single Source Drug", "general_comments": null, "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 699.51, "manufacturer": "Eton Pharmaceuticals, Inc.", "manufacturer_id": "Rx0000270", "ndc": "71863013212", "ndc_5_4_2": "71863-0132-12", "patent_expiration_date": "2028-10-16", "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 5000, "wac_before_increase": 625.38, "wac_effective_date": "2026-05-11", "wac_increase_amount": 4374.62 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "PAI Holdings LLC dba PAI Pharma used a value-based pricing plan by balancing the market competitive landscape, increasing costs, and capacity constraints when managing this pricing decision. When establishing the wholesale acquisition costs, PAI Pharma considers the following major financial and non-financial factors: The safety and efficacy profile of the drug; Availability and accessibility of alternative therapies for the approved indication; Manufacturing and marketing costs; Competitive market data, including marketing and sales data; Past and on-going investments in R&D; and anticipated rebates, discounts, and other fees to be negotiated with supply-chain partners.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-02-13", "drug_category": "Generic", "drug_product_description": "TRIHEXYPHENIDYL HYDROCHLORIDE 0.4mg/mL Oral Solution, 473mL Bottle [Qty: 1]", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": null, "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 480, "manufacturer": "Pharmaceutical Associates, Inc", "manufacturer_id": "Rx0000135", "ndc": "00121065816", "ndc_5_4_2": "00121-0658-16", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 247.37, "wac_before_increase": 42.65, "wac_effective_date": "2026-02-02", "wac_increase_amount": 204.72 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Brand", "drug_product_description": "Hydromorphone Hydrochloride 2 mg/ml per Single-Dose vial 10", "drug_source_type": "Innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377.01, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409336510", "ndc_5_4_2": "00409-3365-10", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 202.06, "wac_before_increase": 42.36, "wac_effective_date": "2026-01-01", "wac_increase_amount": 159.7 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Butorphanol Tartrate 2 mg/mL (4 mg/2 mL) Single Dose Glass Fliptop Vial 10", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409162602", "ndc_5_4_2": "00409-1626-02", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 931.77, "wac_before_increase": 195.34, "wac_effective_date": "2026-01-01", "wac_increase_amount": 736.43 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Brand", "drug_product_description": "Demerol™ 50 mg/mL (1,500 mg/30 mL) Multiple Dose Glass Fliptop Vial 1", "drug_source_type": "Innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409118130", "ndc_5_4_2": "00409-1181-30", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 655.45, "wac_before_increase": 137.41, "wac_effective_date": "2026-01-01", "wac_increase_amount": 518.04 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Dextran 500 mL (10% LMD in 0.9% Sodium Chloride) Flexible Container 12", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409741903", "ndc_5_4_2": "00409-7419-03", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 3972.41, "wac_before_increase": 832.79, "wac_effective_date": "2026-01-01", "wac_increase_amount": 3139.62 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Dextran 500 mL (10% LMD in 5% Dextrose) Flexible Container 12", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409741803", "ndc_5_4_2": "00409-7418-03", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 3809.94, "wac_before_increase": 798.73, "wac_effective_date": "2026-01-01", "wac_increase_amount": 3011.21 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Hydromorphone Hydrochloride 10 mg/mL (10 mg/mL) Single Dose Glass Fliptop Vial 10", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409263401", "ndc_5_4_2": "00409-2634-01", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 780.56, "wac_before_increase": 163.64, "wac_effective_date": "2026-01-01", "wac_increase_amount": 616.92 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Generic", "drug_product_description": "Verapamil Hydrochloride 2.5 mg/mL (5 mg/2 mL) Glass Ampul 5", "drug_source_type": "Non-innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 377, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409401101", "ndc_5_4_2": "00409-4011-01", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 436.5, "wac_before_increase": 91.51, "wac_effective_date": "2026-01-01", "wac_increase_amount": 344.99 }, { "acquisition": null, "change_improvement_description": null, "change_improvement_nonpublic": true, "cost_increase_factors": "A medicine’s price may change for many reasons such as: discovery of new uses and patient populations through both trial data and real world evidence; improvements in manufacturing and supply chain; new formulations; and market-based factors.", "cost_increase_factors_nonpublic": false, "date_reported": "2026-04-30", "drug_category": "Brand", "drug_product_description": "Hydromorphone Hydrochloride 4 mg/mL (4 mg/1 mL) Carpuject™ Luer Lock Glass Syringe (no needle) 10", "drug_source_type": "Innovator Multiple Source Drug", "general_comments": "The information contained in this report is subject to the following limitations and assumptions.\n(1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Pfizer believes is otherwise in the public domain or publicly available. Where possible, Pfizer has used the non-public indicator to indicate it does not believe the corresponding data element is otherwise in the public domain or publicly available. \n(2) While Pfizer does not believe any change improvments for a specific drug product’s price increases are in the public domain or publicly available, Pfizer has provided general information about its drug pricing philosophy and policy. More information about Pfizer’s general drug pricing philosophy and policy is available on Pfizer’s website.", "gross_sales_nonpublic": true, "gross_sales_us_dollars": null, "history": null, "increase_percent": 376.95, "manufacturer": "Pfizer", "manufacturer_id": "Rx0000006", "ndc": "00409130431", "ndc_5_4_2": "00409-1304-31", "patent_expiration_date": null, "supporting_documents_url": null, "three_year_increase_percent": null, "unit_sales_volume_nonpublic": false, "unit_sales_volume_us": null, "wac_after_increase": 150, "wac_before_increase": 31.45, "wac_effective_date": "2026-01-01", "wac_increase_amount": 118.55 } ], "source_updated_at": "2026-10-05", "source_url": "https://data.chhs.ca.gov/dataset/prescription-drug-wholesale-acquisition-cost-wac-increases", "total_count": 100, "year": 2026 } ``` ### Launch search - Capability: `drug-launches/launch_search` - Description: New prescription drugs introduced to market at a WAC above the Medicare Part D specialty-drug threshold, as manufacturers reported them to California HCAI (CTRx): per NDC, the introduction date, WAC at introduction, the manufacturer's marketing and pricing plan, estimated number of patients, FDA breakthrough therapy and priority review flags, and acquisition details. Filter by drug, manufacturer, NDC, introduction date, minimum WAC, Brand or Generic and the two FDA flags; one year's file per call (the current year to date by default, annual files back to 2019). No match is an empty result. - Instructions: Pick it for launch prices of new specialty-priced drugs and how manufacturers say they will market and price them: "which drugs launched in 2026 above the Part D specialty threshold and at what WAC", "which 2025 launches had breakthrough therapy designation", "the most expensive launches of 2025". Drugs launched below the threshold are not reported. For later list price increases of a drug use wac-increases/search. - Cost: 5 credits per call - Capability file: [Launch search](https://firecrawl.dev/alexandria/agents/providers/data-chhs-ca-gov/drug-launches/launch_search) Accepted options: - `breakthrough_therapy` (boolean): true: only drugs with FDA breakthrough therapy designation; false: only drugs without it. Example: `false` - `drug` (string): Drug product description to match, case-insensitively anywhere in it: a brand (`skyrizi`, `Fyarro`), an ingredient as the manufacturer wrote it, a strength or a package form. Example: `` - `drug_category` (string): Brand or Generic, as the manufacturer classified the drug. Only the current year's monthly file reports it; with an annual year this is invalid_input. Example: `Brand` - `introduced_from` (string): Only drugs introduced to market on or after this date (YYYY-MM-DD). Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `introduced_to` (string): Only drugs introduced to market on or before this date (YYYY-MM-DD). Pattern: ^[0-9]{4}-[0-9]{2}-[0-9]{2}$. Example: `` - `limit` (number): Drugs per page. Example: `25` - `manufacturer` (string): Manufacturer name to match, case-insensitively anywhere in it: `AbbVie`, `pfizer`, `Teva`. Example: `` - `min_wac` (number): Only drugs whose WAC at introduction is at least this many USD. Example: `10` - `ndc` (string): An NDC-11 as 11 digits (`80803015350`) or hyphenated 5-4-2 (`80803-0153-50`), a hyphenated 10-digit NDC (`0074-2100-01`, 4-4-2, 5-3-2 or 5-4-1, padded to 5-4-2), or an NDC-9 product code (`80803-0153`, `808030153`) matching all its packages. A bare 10-digit NDC is ambiguous and rejected. Example: `80803015350` - `offset` (number): Drugs to skip; pass `next_offset` from the previous page. Example: `0` - `priority_review` (boolean): true: only drugs that had FDA priority review; false: only drugs without it. Example: `false` - `sort` (string): Order of results: latest introduction first (default), or highest WAC at introduction first. Example: `introduced_date_desc` - `year` (number): Calendar year of the report file to read: the current year reads HCAI's monthly update (the year to date), earlier years their Q1-Q4 annual file. Defaults to the latest year published. A year without a file is invalid_input listing the years available. Example: `2019` Response schema example: ```json { "file_name": "new-drug-data-jan-sept-2026.csv", "file_url": "https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-sept-2026.csv", "license": { "attribution": "Source: California Department of Health Care Access and Information (HCAI), Cost Transparency Report on prescription drugs (CTRx), Prescription Drugs Introduced to Market, published on the California Open Data Portal under CC BY.", "name": "Creative Commons Attribution (CC BY)", "url": "https://data.ca.gov/dataset/prescription-drugs-introduced-to-market" }, "next_offset": null, "results": [ { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Pasatru (garetosmab-grts) 300 mg/5 mL (60 mg/mL) Injection, 5 mL Single Dose Vial", "estimated_patients": 220, "general_comments": "All information submitted by Regeneron Pharmaceuticals, Inc. to the California Office of Statewide Health Planning and Development under Cal. Code. Regs. Tit. 22, § 96076, including all information contained in this submission, is confidential and proprietary commercial or financial information not subject to disclosure, including under the California Public Records Act. Regeneron requests that the confidentiality of this submission and of all Regeneron’s related information herein be maintained to the maximum extent permitted by law. To the extent that any of this designated information is requested, whether under the California Public Records Act or otherwise, Regeneron requests that it be notified of the request and afforded an opportunity to submit objections to disclosure.", "introduced_to_market_date": "2026-08-19", "manufacturer": "Regeneron Pharmaceuticals, Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing Planned marketing activities that will support the approval of PASATRU® (garetosmab-grts) infusion include raising awareness among healthcare professionals of the product and of fibrodysplasia ossificans progressiva. Educational efforts will focus on the reduction in the number of new heterotopic ossification lesions and in HO volume at week 56 versus placebo, along with the reduction in clinician-assessed flare-ups, with a safety profile characterized in the Phase 3 OPTIMA trial. Awareness activities will also address the once-monthly intravenous dosing regimen, administered in the clinic or in the home. These activities will be conducted through physician-focused product and disease education websites, other digital media, print media, congress presence and peer-to-peer scientific exchange, and use of sales representatives to promote the FDA-approved indication in adults. Anticipated direct-to-consumer marketing activities include a consumer-focused product website, other digital media, and patient support program materials describing infusion, nursing, and reimbursement services. Pricing \nRegeneron approaches pricing with fairness, affordability and access at the forefront. Our pricing philosophy is guided by several principles. \n\nFirst, medicines should be priced fairly. We take a value-based pricing approach that reflects their benefit to patients, society and the healthcare system. We consider the long-term investment and risk inherent in science and technology innovation, which is required to bring novel medicines to patients. \n\nSecond, medicines are only useful if patients in need can access and afford them. We are committed to supporting patients’ access by providing financial assistance for eligible patients.\n\nThird, our growth is driven by scientific innovation, not pricing. Any price changes Regeneron makes is designed to keep pace with the medicine’s value and our costs, and in careful consideration of commercial competitiveness.\n\nRegeneron also seeks to work collaboratively with other stakeholders in the healthcare system and welcome their input on fair and cost-effective pricing. These principles taken together help to ensure advancing our goal of setting fair, value-based prices for our medicines and breaking down barriers to patient access.", "ndc": "61755001201", "ndc_5_4_2": "61755-0012-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 53307 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "ZENBEXUS 0.75 mg capsules, 21 count bottle", "estimated_patients": 3866, "general_comments": "Estimated Number of Patients: BMS anticipates approximately ~320 patients per month in Sep. 2026 to Aug. 2027 on an average, subject to change. However, BMS is unable to provide an exact number of patients who will be prescribed these strengths/SKUs.", "introduced_to_market_date": "2026-08-17", "manufacturer": "Bristol Myers Squibb", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply.", "ndc": "00003570021", "ndc_5_4_2": "00003-5700-21", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 29500 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "ZENBEXUS 1 mg capsules, 21 count bottle", "estimated_patients": 3866, "general_comments": "Estimated Number of Patients: BMS anticipates approximately ~320 patients per month in Sep. 2026 to Aug. 2027 on an average, subject to change. However, BMS is unable to provide an exact number of patients who will be prescribed these strengths/SKUs.", "introduced_to_market_date": "2026-08-17", "manufacturer": "Bristol Myers Squibb", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "We consider multiple factors when setting a list price for a medicine, including: (i) The benefits the medicine brings to patients, healthcare systems and society - in terms of clinical outcomes and quality of life, longevity of life, and savings generated for other parts of the healthcare system such as reduced hospitalization and treatment costs. (ii) Market and business considerations, including: Ongoing research-investment costs; BMS invests more than 21% of its annual revenues in R&D, among the highest of any large company in any industry in the world; and Medical- and patient-service costs; this includes funding growing patient assistance programs; Inflationary and capital-investment costs associated with manufacturing, storage and supply.", "ndc": "00003571021", "ndc_5_4_2": "00003-5710-21", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 29500 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Jideytro™ (zidesamtinib) 100mg tablets 30 count bottle", "estimated_patients": 2000, "general_comments": null, "introduced_to_market_date": "2026-08-03", "manufacturer": "Nuvalent, Inc.", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "85001010201", "ndc_5_4_2": "85001-0102-01", "priority_review": false, "supporting_documents_url": null, "wac_at_introduction": 33708 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Jideytro™ (zidesamtinib) 25mg tablets 30 count bottle", "estimated_patients": 2000, "general_comments": null, "introduced_to_market_date": "2026-08-03", "manufacturer": "Nuvalent, Inc.", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "85001010101", "ndc_5_4_2": "85001-0101-01", "priority_review": false, "supporting_documents_url": null, "wac_at_introduction": 11236 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Tryngolza® (olezarsen) Subcutaneous Solution Auto-injector 50 MG/0.8ML", "estimated_patients": 3000000, "general_comments": null, "introduced_to_market_date": "2026-07-09", "manufacturer": "Ionis Pharmaceuticals, Inc.", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "71860010201", "ndc_5_4_2": "71860-0102-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 3333.33 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Trutakna 150 mg/ml 1 carton of 4 single-dose prefilled autoinjectors", "estimated_patients": 22300, "general_comments": "MMIT patient data (annualized) estimates approximately 22,300 patients in the U.S. diagnosed with IgAN, the indication for which our product may be prescribed.", "introduced_to_market_date": "2026-07-07", "manufacturer": "VERA THERAPEUTICS, INC.", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "85052010104", "ndc_5_4_2": "85052-0101-04", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 32700 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Lumvoa (veligrotug-vvze), 500 mg/10 mL (50 mg/mL) Injection, One 10 mL Single-Dose Vial.", "estimated_patients": 4500, "general_comments": null, "introduced_to_market_date": "2026-06-29", "manufacturer": "Viridian Therapeutics, Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing Plan: \n• Marketing activities targeting consumers: patient website (https://www.lumvoa.com), disease state education (Thyroid Eye Disease), product information (dosing/administration, safety, efficacy), and assistance available to qualifying patients from Viridian Therapeutics. \n• Marketing activities targeting the healthcare industry: website (https://www.lumvoahcp.com), professional detailing, disease state education (Thyroid Eye Disease), product information (dosing/administration, safety, efficacy), and assistance available to qualifying patients from Viridian Therapeutics.\n\nPricing Plan:\nViridian Therapeutics assesses various quantitative and qualitative factors. Pricing practices involve evaluation of product safety, efficacy, tolerability, ease of use, patient quality of life, differentiation from existing therapeutic alternatives, and market research. Other considerations include patient access and affordability, ongoing business operations (costs of manufacturing, distribution, marketing, access contracting, etc.), and investments in research and development.", "ndc": "85166000101", "ndc_5_4_2": "85166-0001-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 44800 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "DECNUPAZ, 2mg", "estimated_patients": 278, "general_comments": null, "introduced_to_market_date": "2026-06-16", "manufacturer": "AbbVie", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "00074028202", "ndc_5_4_2": "00074-0282-02", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 92325.4 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Auvelity, 21 tablets of 30 mg dextromethorphan hydrobromide and 105 mg bupropion hydrochloride; 30 tablets of 45 mg dextromethorphan hydrobromide and 105 mg bupropion hydrochloride", "estimated_patients": 5000000, "general_comments": null, "introduced_to_market_date": "2026-06-08", "manufacturer": "Axsome Therapeutics, Inc.", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "81968034501", "ndc_5_4_2": "81968-0345-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 1060.8 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Hepcludex (bulevirtide-gmod), injection, power, lyophilized, for solution, 8.5 mg/vial, 30 single-dose vials", "estimated_patients": 450, "general_comments": null, "introduced_to_market_date": "2026-05-22", "manufacturer": "Gilead Sciences, Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing Plan: Marketing activities targeting consumers: Patient education video, Patient education brochure, Patient education dosing administration demonstration kits, Patient/Consumer website\n\nMarketing activities targeting HCPs: HCP education video (same as patient video), HCP education brochure and sales aid, HCP education dosing administration demonstration kits (same as patient kits), HCP website, HCP online advertising, Prescribing and access information brochures\n\nPricing Plan: HEPCLUDEX® (bulevirtide-gmod) 8.5 mg for the treatment of adults living with chronic hepatitis delta virus (HDV) infection, launched 5/22/2026, making it the first and only FDA-approved treatment for HDV in the United States.   \n \nHepcludex is an important new treatment for people living with hepatitis delta virus (HDV), a rare and serious liver disease that can quickly lead to liver failure, liver cancer, or the need for a transplant.  \n\nGilead’s pricing decisions reflect the safety and efficacy of Hepcludex and represents a critical advancement, introducing a long-awaited option that begins to address a significant unmet medical need in offering the possibility to slow disease progression and preserve quality of life where no approved options previously existed for individuals living with HDV in the US.", "ndc": "61958310401", "ndc_5_4_2": "61958-3104-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 23286 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "AVLAYAH (tividenofusp alfa-eknm) 150 mg single-dose vial, Powder for solution", "estimated_patients": 400, "general_comments": "See AVLAYAH FDA Approval Call presentation: https://investors.denalitherapeutics.com/static-files/2b249883-b380-4136-a55e-0f57ded4302a", "introduced_to_market_date": "2026-04-06", "manufacturer": "Denali Therapeutics Inc.", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "84976000101", "ndc_5_4_2": "84976-0001-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 5200 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "LOARGYS® (pegzilarginase-nbln) (2mg/0.4 mL) (1 single-dose vial)", "estimated_patients": 175, "general_comments": null, "introduced_to_market_date": "2026-03-31", "manufacturer": "Immedica Pharma US Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing activities targeting consumers: Partnership with advocacy groups on disease education, participation at conferences for advocacy groups, and print materials.\n\nMarketing activities targeting HCPs: Sales force, website:digital and non-personal promotion, print marketing materials, professional detailing, national/regional conference sponsorships, and medical education.\n\nPrice reflects ultra-rare disease prevalence of approximately 1:1,000,000, Breakthrough Therapy designation, priority review, orphan designation, fast track designation.", "ndc": "81583010201", "ndc_5_4_2": "81583-0102-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 11469.31 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "KYGEVVI (doxecitine and doxribtimine) 4 gm (2 gm-2 gm) Powder Pk, 30 PACKETS", "estimated_patients": 80, "general_comments": null, "introduced_to_market_date": "2026-03-16", "manufacturer": "UCB, Inc", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "50474035030", "ndc_5_4_2": "50474-0350-30", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 16438.5 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Zycubo, (copper histidinate), INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, 2.9 mg/1, 1, 1 VIAL, GLASS in 1 CARTON (42358-329-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS", "estimated_patients": 100, "general_comments": "The product was introduced to market 5 days after the drug compendia list date.", "introduced_to_market_date": "2026-02-10", "manufacturer": "Sentynl Therapeutics, Inc.", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "42358032901", "ndc_5_4_2": "42358-0329-01", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 1867 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "YARTEMLEA (narsoplimab), INJECTION, 370 mg/2mL, 1 VIAL in 1 CARTON (62225-300-00) / 2 mL in 1 VIAL", "estimated_patients": 1900, "general_comments": null, "introduced_to_market_date": "2026-01-21", "manufacturer": "Omeros Corporation", "marketing_pricing_nonpublic": true, "marketing_pricing_plan": null, "ndc": "62225030000", "ndc_5_4_2": "62225-0300-00", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 36805 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "MYQORZO tablet 10mg, 30 count bottle", "estimated_patients": 1103, "general_comments": null, "introduced_to_market_date": "2026-01-12", "manufacturer": "Cytokinetics, Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing: Cytokinetics is a new commercial biopharmaceutical company with a single product, MYQORZO(tm), which was approved by the FDA on December 19, 2025. Prior to our approval, in 2024, we created a market development and disease education campaign, developed field representative commercial training modules, engaged payers with compliant, pre-approval information and continued planning to build out the necessary technologies to support product launch. We have now deployed a field-based commercial and medical affairs team in key geographies across the US. Key aspects of our consumer marketing approach include but are not limited to a focus on awareness and diagnosis, targeted digital outreach, hiring and training of patient navigators, online education tools and collaboration with advocacy groups. We have also designed and share information concerning a comprehensive patient and HCP support program that facilitates access to our product. The program includes reimbursement support, affordability programs, and patient education resources. Our customer-facing strategy has been informed by insights gathered from potential prescribers of our product through market research, focus groups, and advisory boards. We also considered secondary data, patient diagnosis data, prescriptions and treatment data, and thereby identified approximately 10,000 treaters, which represent an estimated ~75% of HCM cardiologist patient volume, as the primary targets for our sales and marketing efforts. \n\nPricing: Cytokinetics has made a significant investment in clinical trials, research and development and commercialization costs along with evaluating the competitive landscape within the drug class and will in part base list price on these factors. Therapeutic value, standard of care, patient population, market size, clinical efficacy and safety, regulatory status and market exclusivity are also components of determination of a WAC price. This product’s ability to substantially improve quality of life through the reduction of symptom burden and improved functional class provided to patients and their caregivers was a strong consideration when establishing a WAC.", "ndc": "82112011030", "ndc_5_4_2": "82112-0110-30", "priority_review": false, "supporting_documents_url": null, "wac_at_introduction": 8909.59 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "MYQORZO tablet 15mg, 30 count bottle", "estimated_patients": 967, "general_comments": null, "introduced_to_market_date": "2026-01-12", "manufacturer": "Cytokinetics, Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing: Cytokinetics is a new commercial biopharmaceutical company with a single product, MYQORZO(tm), which was approved by the FDA on December 19, 2025. Prior to our approval, in 2024, we created a market development and disease education campaign, developed field representative commercial training modules, engaged payers with compliant, pre-approval information and continued planning to build out the necessary technologies to support product launch. We have now deployed a field-based commercial and medical affairs team in key geographies across the US. Key aspects of our consumer marketing approach include but are not limited to a focus on awareness and diagnosis, targeted digital outreach, hiring and training of patient navigators, online education tools and collaboration with advocacy groups. We have also designed and share information concerning a comprehensive patient and HCP support program that facilitates access to our product. The program includes reimbursement support, affordability programs, and patient education resources. Our customer-facing strategy has been informed by insights gathered from potential prescribers of our product through market research, focus groups, and advisory boards. We also considered secondary data, patient diagnosis data, prescriptions and treatment data, and thereby identified approximately 10,000 treaters, which represent an estimated ~75% of HCM cardiologist patient volume, as the primary targets for our sales and marketing efforts. \n\nPricing: Cytokinetics has made a significant investment in clinical trials, research and development and commercialization costs along with evaluating the competitive landscape within the drug class and will in part base list price on these factors. Therapeutic value, standard of care, patient population, market size, clinical efficacy and safety, regulatory status and market exclusivity are also components of determination of a WAC price. This product’s ability to substantially improve quality of life through the reduction of symptom burden and improved functional class provided to patients and their caregivers was a strong consideration when establishing a WAC.", "ndc": "82112011530", "ndc_5_4_2": "82112-0115-30", "priority_review": false, "supporting_documents_url": null, "wac_at_introduction": 8909.59 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "MYQORZO tablet 20mg, 30 count bottle", "estimated_patients": 1187, "general_comments": null, "introduced_to_market_date": "2026-01-12", "manufacturer": "Cytokinetics, Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing: Cytokinetics is a new commercial biopharmaceutical company with a single product, MYQORZO(tm), which was approved by the FDA on December 19, 2025. Prior to our approval, in 2024, we created a market development and disease education campaign, developed field representative commercial training modules, engaged payers with compliant, pre-approval information and continued planning to build out the necessary technologies to support product launch. We have now deployed a field-based commercial and medical affairs team in key geographies across the US. Key aspects of our consumer marketing approach include but are not limited to a focus on awareness and diagnosis, targeted digital outreach, hiring and training of patient navigators, online education tools and collaboration with advocacy groups. We have also designed and share information concerning a comprehensive patient and HCP support program that facilitates access to our product. The program includes reimbursement support, affordability programs, and patient education resources. Our customer-facing strategy has been informed by insights gathered from potential prescribers of our product through market research, focus groups, and advisory boards. We also considered secondary data, patient diagnosis data, prescriptions and treatment data, and thereby identified approximately 10,000 treaters, which represent an estimated ~75% of HCM cardiologist patient volume, as the primary targets for our sales and marketing efforts. \n\nPricing: Cytokinetics has made a significant investment in clinical trials, research and development and commercialization costs along with evaluating the competitive landscape within the drug class and will in part base list price on these factors. Therapeutic value, standard of care, patient population, market size, clinical efficacy and safety, regulatory status and market exclusivity are also components of determination of a WAC price. This product’s ability to substantially improve quality of life through the reduction of symptom burden and improved functional class provided to patients and their caregivers was a strong consideration when establishing a WAC.", "ndc": "82112012030", "ndc_5_4_2": "82112-0120-30", "priority_review": false, "supporting_documents_url": null, "wac_at_introduction": 8909.59 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "MYQORZO tablet 5mg, 30 count bottle", "estimated_patients": 954, "general_comments": null, "introduced_to_market_date": "2026-01-12", "manufacturer": "Cytokinetics, Inc.", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Marketing: Cytokinetics is a new commercial biopharmaceutical company with a single product, MYQORZO(tm), which was approved by the FDA on December 19, 2025. Prior to our approval, in 2024, we created a market development and disease education campaign, developed field representative commercial training modules, engaged payers with compliant, pre-approval information and continued planning to build out the necessary technologies to support product launch. We have now deployed a field-based commercial and medical affairs team in key geographies across the US. Key aspects of our consumer marketing approach include but are not limited to a focus on awareness and diagnosis, targeted digital outreach, hiring and training of patient navigators, online education tools and collaboration with advocacy groups. We have also designed and share information concerning a comprehensive patient and HCP support program that facilitates access to our product. The program includes reimbursement support, affordability programs, and patient education resources. Our customer-facing strategy has been informed by insights gathered from potential prescribers of our product through market research, focus groups, and advisory boards. We also considered secondary data, patient diagnosis data, prescriptions and treatment data, and thereby identified approximately 10,000 treaters, which represent an estimated ~75% of HCM cardiologist patient volume, as the primary targets for our sales and marketing efforts. \n\nPricing: Cytokinetics has made a significant investment in clinical trials, research and development and commercialization costs along with evaluating the competitive landscape within the drug class and will in part base list price on these factors. Therapeutic value, standard of care, patient population, market size, clinical efficacy and safety, regulatory status and market exclusivity are also components of determination of a WAC price. This product’s ability to substantially improve quality of life through the reduction of symptom burden and improved functional class provided to patients and their caregivers was a strong consideration when establishing a WAC.", "ndc": "82112010530", "ndc_5_4_2": "82112-0105-30", "priority_review": false, "supporting_documents_url": null, "wac_at_introduction": 8909.59 }, { "acquisition": null, "breakthrough_therapy": true, "drug_category": "Brand", "drug_product_description": "Hernexeos 60mg, 30 CT Tablets", "estimated_patients": 526, "general_comments": "Pursuant to SB 17 and the implementing regulations, we limit the information included in this submission to that which is otherwise in the public domain or publicly available.", "introduced_to_market_date": "2026-01-08", "manufacturer": "Boehringer Ingelheim", "marketing_pricing_nonpublic": false, "marketing_pricing_plan": "Specific Marketing and Pricing Plans for Hernexeos are not in the public domain or publicly available. Boehringer Ingelheim considered several factors in determining the price of our medicines. These factors include: the life transforming value that is delivered to patients, investments made with research and development and beyond, the patient population size, manufacturing, the risks undertaken, consideration for access to patients and the continued need for scientific innovation for generations to come. Boehringer Ingelheim invests up to 27.6% of its net sales into research and development, including clinical trials.", "ndc": "00597925759", "ndc_5_4_2": "00597-9257-59", "priority_review": true, "supporting_documents_url": null, "wac_at_introduction": 10833.51 } ], "source_updated_at": "2026-10-05", "source_url": "https://data.chhs.ca.gov/dataset/prescription-drugs-introduced-to-market", "total_count": 21, "year": 2026 } ```